Bladder Cancer - Results from #200

Outcomes of Bladder-Preserving Radiation Therapy in Locally Advanced MIBC - Expert Commentary January 9, 2025

Towards Reliable Methodology: Microbiome Analysis of Fresh Frozen vs. Formalin-Fixed Paraffin-Embedded Bladder Tissue Samples: A Feasibility Study. January 9, 2025

Sequential Endoluminal Doxorubicin and Gemcitabine Alternating Weekly with Sequential Mitomycin and Docetaxel for Recurrent Non-Muscle Invasive Urothelial Carcinoma. January 9, 2025

PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCG. January 8, 2025

Bowel regimens before radical cystectomy: An analysis of a modern cohort. January 8, 2025

The Molecular Features and Spatial Architecture of Bladder Ewing Sarcoma - Expert Commentary January 7, 2025

Home Urine Dipstick Screening for Bladder and Kidney Cancer in High-Risk Populations in England: A Microsimulation Study of Long-Term Impact and Cost-Effectiveness. January 7, 2025

Patterns of Failure After Definitive Trimodality Therapy for Muscle-Invasive Bladder Cancer. January 7, 2025

Comprehensive genomic characterization of early-stage bladder cancer. January 7, 2025

Single-cell RNA sequencing and spatial transcriptomics of bladder Ewing sarcoma. January 7, 2025

Treatment Patterns for Metastatic Urothelial Carcinoma Across Eight Mexican Centers: The ALEBRIJE Study. January 6, 2025

Real-world data on utilization of neoadjuvant chemotherapy for muscle invasive bladder cancer: impact on surgical complications and oncological efficacy. January 6, 2025

TYTOCARE™ home telemonitoring device after radical cystectomy to optimise postoperative outcomes. January 3, 2025

Adjuvant Immunotherapy in High-Risk Muscle-Invasive Urothelial Cancer: An Updated Meta-Analysis of Randomized Controlled Trials. January 3, 2025

Diagnostic accuracy and inter-reader agreement of the nacVI-RADS for bladder cancer treated with neoadjuvant chemotherapy: a prospective validation study. January 2, 2025

Identifying optimal candidates for active surveillance in low-grade intermediate-risk non-muscle invasive bladder cancer. January 2, 2025

AI allows pre-screening of FGFR3 mutational status using routine histology slides of muscle-invasive bladder cancer. January 1, 2025

Does time matter in early radical cystectomy? Comparing outcome, clinical and pathological characteristics of immediate versus deferred radical cystectomy. December 31, 2024

Alterations in DNA Damage Repair Genes Before and After Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. December 31, 2024

The Financial Burden of Localized and Metastatic Bladder Cancer. December 30, 2024

Page 11 of 535